… However, this analysis was post-hoc and EGFR mutation status was not a … this phase 2
trial to examine the combination of erlotinib and bevacizumab in patients with EGFR mutation-…

… Although multiple high-quality randomised phase 3 trials have shown that immunotherapy
improves outcomes for patients with advanced NSCLC, those with EGFR mutations were …

… This multicentre phase II trial was conducted to evaluate the efficacy and safety of low-dose
erlotinib in chemotherapy-pretreated patients with NSCLC harbouring EGFR mutations. …

… We performed a multicentre phase II study examining the use of gefitinib for advanced
NSCLC in patients with EGFR mutations, prospectively recruiting patients at the time of genetic …

… , phase 1–2 study, in which we enrolled patients with advanced NSCLC harbouring activating
mutations of EGFR that had progressed after EGFR … mutations were enrolled), and a phase …

7514 Background: EGFR mutant NSCLC is exquisitely sensitive to EGFR tyrosine kinase
inhibitors (TKIs). Retrospective data suggests adjuvant TKIs may improve outcomes. This trial is …

… In our open-label, multicentre, randomised phase 3 trial we … diagnosis of stage IIIB (with
pleural effusion) or stage IV … activating EGFR mutations (exon 19 deletion or L858R mutation in …

… BELIEF was an international, multicentre, single-arm, phase … stage IIIB or stage IV lung
adenocarcinoma with a confirmed, activating EGFR mutation (exon 19 deletion or L858R mutation…

… , phase 1/2 study was conducted at nine academic medical centres located in Europe, Asia,
… and had stage IIIB–IV EGFR-mutant NSCLC (with varying statuses of EGFR mutation and …

… This study was a multicenter, open-label, phase-II clinical trial evaluating the safety and …
treatment of advanced NSCLC with EGFR-sensitive mutations after failure of EGFR-TKI therapy (…